primobolan depot cycle

Active metabolite sodium picosulphate binds to receptors on the intestinal wall, blocking the absorption of water and electrolytes and increases their secretion into the primobolan depot cycle intestinal lumen, resulting in enhanced peristalsis promoting accelerated intestinal contents. Laxative effect occurs within 10-12 hours after ingestion. Sodium picosulphate as the hydrophilic primobolan depot cycle substance is practically not absorbed through the lipophilic membrane of intestinal cells. Therefore, after the ingestion of sodium picosulphate relatively quickly passes through the stomach and small intestine intact. Approximately 70% of the dose primobolan depot cycle enters the colon after 3 hours after administration. In the large intestine by hydrolysis under the influence of sodium picosulfate intestinal microorganisms lipophilic active metabolite formed, which easily penetrates through biological cell membranes, stimulating neuroreceptors colonic mucosa membranes.

Hypersensitivity to sodium picosulphate, triarilmetanu, parabens and other ingredients, intestinal obstruction, incarcerated hernia, appendicitis, peritonitis, acute inflammatory diseases of the abdominal cavity, including pancreatitis and acute enterocolitis, intestinal and uterine bleeding, abdominal pain, unexplained genesis, nausea, vomiting of unknown origin, cystitis, severe dehydration, spastic constipation, a condition after operations on the abdominal organs, I trimester pregnancy, breastfeeding, children younger than 4 years.

Children older than 4 years.

Pregnancy and lactation
In II and III trimester of pregnancy, the primobolan depot cycle drug can be taken only in cases where the potential benefits of therapy for the mother is much higher than the potential risk to the fetus.

Dosing and Administration
Inside, diluted in a little water before bedtime. Adults and children over 10 years : 12-24 drops by (5-10 mg). Children from 4 years to 10 years: 6-12 drops (2, 5-5 mg). depending on the effect of the dose in subsequent receptions increases or decreases.


Overdose Symptoms: cm. See “Side effects”, as well as paroxysmal abdominal pain, ischemia of the colon mucosa, hyperaldosteronism, urolithiasis, renal tubular damage. Treatment: gastric lavage, correction of fluid and electrolyte balance, antispasmodics.

Side effects:
As a rule, short-term use of sodium primobolan depot cycle picosulphate has almost no side effects. Side effects develop during long-term treatment. From the digestive system: the aggravation of constipation, megacolon. At higher doses – colic, diarrhea, intestinal spasms. On the part of metabolism: a violation of water-electrolyte balance, dehydration, hyponatremia. Cardio-vascular system: decrease in blood pressure. From the nervous system: convulsions.

Interaction with other medicinal products
Broad-spectrum antibiotics reduce primobolan depot cycle the laxative effect; diuretics and corticosteroids increase the risk of water and electrolyte imbalance; possible increased sensitivity to cardiac glycosides.

Do not use without medical supervision primobolan depot cycle for more than 10 days. In the application of the sodium picosulfate in high doses and for a long time can be symptoms appear water-electrolyte imbalance, including hyponatremia. We can not exclude the possibility of spontaneous bowel movements. If the character of stool while taking sodium picosulphate does not change for a long time, you should consult a doctor to determine the cause of constipation.

Effects on ability to drive vehicles and work primobolan depot cycle with the technique of
Sodium picosulphate not affect the ability to motor vehicles and other equipment management.

primobolan depot bayer

Hypromellose is a protector of the corneal epithelium, having a high viscosity, increases the contact time of the solution with the cornea. The refractive index of the solution primobolan depot bayer is similar to the natural tears.
Restores stabilizes optical characteristics and reproduces the tear film. It extends the effects of other eye drops and protects the cornea from them irritating.
Benzalkonium chloride – has a disinfecting action and some of the properties of cationic detergents. It has bactericidal activity against Gram-positive microorganisms, some yeasts. Less active against P.aerugenosa, M.tuberculosis, Clostridia spp., Sporogenous microorganisms and viruses.

Lack of tearing, lagophthalmos, deformation primobolan depot bayer of the eyelids, ectropion, a condition after blepharoplasty, erosion and trophic ulcers of the cornea, a condition after surgery and thermal corneal burns and conjunctiva, bullous degenerative changes in the cornea, keratopathy, micro-defects of the corneal epithelium, the state after keratoplasty , keratoektomii.
The need for a prolongation of the effect or reducing the irritant effect of other eye drops. Combined treatment of the syndrome of “dry eye”: Sjogren’s syndrome, xerosis, keratosis (often in combination with therapeutic contact lenses).

Individual hypersensitivity to the drug, acute inflammatory and infectious diseases of the anterior eye.
Pregnancy, lactation, children’s age.

With care
in the acute phase of chemical burns of the cornea and conjunctiva (to complete the removal of toxic substances and necrotic tissue).

Dosing and Administration
Bury 1-2 drops 4-8 times a day in the conjunctival sac. Do not exceed the recommended dose.
In appointing the drug to treat primobolan depot bayer the syndrome of “dry eye” treatment duration is determined by the physician.
In appointing the drug with the aim of antimicrobial application period is 5-7 days.

Side effects
: Allergic reactions, feeling the bonding century (due to the high viscosity of the solution), a burning sensation or irritation.
Allergic reactions possible with long-term use of the drug. In this case shows the discontinuation of primobolan depot bayer treatment and administration of appropriate therapy.
With prolonged use may develop degenerative changes of the corneal epithelium.

Data on overdose of the drug available.

Interaction with other drugs
The drug is not compatible with eye drops containing metal salts.

Special instructions:
The drug is not recommended for primobolan depot bayer use while wearing contact lenses. Before using the product, remove contact lenses and put them back no earlier than 20-30 minutes.
In view of a possible watery eyes after instillation of the drug is not recommended to apply it immediately before the driving of the vehicles or maintenance of mechanical equipment.

primobolan depot side effects

Quetiapine is a selective decrease in the activity of mesolimbic A10 dopaminergic neurones versus the primobolan depot side effects nigrostriatal neurones involved in motor function. There is no long-term increase prolactin concentration in blood plasma. In clinical studies have shown efficacy against both positive and negative symptoms of schizophrenia. When quetiapine orally is well absorbed from the gastrointestinal tract and is extensively metabolised by the liver. The major metabolites found in the plasma does not possess a pronounced pharmacological activity.
Food intake did not significantly affect the bioavailability of quetiapine. The half-life of about 7 hours. Approximately  of quetiapine binds to plasma proteins. The pharmacokinetics of quetiapine linear, differences in pharmacokinetic parameters in men and women is not observed.
The average clearance of quetiapine in elderly patients is  less than in patients .

  • Schizophrenia.
  • Manic episodes of moderate to severe in the structure of bipolar disorder.It does not prevent the development of manic and depressive episodes.
  • Hypersensitivity to any component of the drug,
  • The simultaneous use of inhibitors of cytochrome P450 ZA4 (e.g., HIV protease inhibitors, azole antifungals structure, erythromycin, clarithromycin, nefazodone)
  • Children’s age (efficacy and safety have not been established),
  • Pregnancy and lactation (effectiveness and safety have been established).Precautions: hypotension, heart failure, cardiac hypertrophy, cardiovascular and cerebrovascular disease, or other conditions predisposing to hypotension, advanced age, liver failure, epilepsy, seizures in history, co-administration of drugs prolonging QT-interval, patients with congenital increase in QT-interval or family history of its increase, hypocalcemia, hypomagnesemia, risk factors for thromboembolism, venous vessels.Dosage and administration
    . Inside, 2 times a day, regardless of meals Treatment of schizophrenia The daily dose for the first 4 days of therapy primobolan depot side effects is as follows: Day 1 – 50 mg, 2 nd day – 100 mg, day 3 – 200 mg, day 4 – 300 mg. since the 4th day, the dose is adjusted individually to achieve an effective dosage is typically 300 – 450 mg / day. Depending on the clinical effect, and individual patient tolerance dose can vary from 150 to 750 mg / day. The maximum recommended daily dose is 750 mg. The treatment of manic disorders daily dose for the first 4 days of treatment is as follows: Day 1 – 100 mg, 2 day – 200 mg, 3 day – 300 mg, day 4 – 400 mg. Subsequently, by the 6th day of treatment the daily dose can be increased to 800 mg. The increase in the daily dose should not be more than 200 mg per day. Depending on the clinical effect and individual tolerability, the dose can vary from 200 to 800 mg / day. Typically, the effective dose is from 400 to 800 mg / day. The maximum recommended daily dose is 800 mg / day. Elderly patients in elderly patients the initial dose is 25 mg / day. Daily dose should be increased by 25 – 50 mg to achieve an effective dose which is usually smaller than in younger patients. Renal and / or hepatic impairment is recommended to start treatment with a dose of 25 mg / day. followed by the daily increase of 25 – 50 mg to achieve an effective dose.

    Side effects
    very often – more than 10/100, often – more than 1/100 and less than 1/10, rarely – more than 1/1000 and less than 1/100, rarely – more than 1/10000 and less than 1/1000, very rare – less . 1/10000 On the part of the central nervous system: very often – dizziness, drowsiness, headache; often – syncope; rarely – seizures; rarely – tardive dyskinesia; with unknown frequency are found anxiety, hostility primobolan depot side effects, agitation, insomnia, akathisia, tremor, depression, paresthesia, Cardio-vascular system: often – tachycardia, orthostatic hypotension; cases of thromboembolic venous vessels, including pulmonary embolism and deep venous vessels. The respiratory system: pharyngitis, rhinitis, part of the digestive system: often – dry mouth, constipation, dyspepsia; -zheltuha rarely, nausea, vomiting, abdominal pain; very rarely – hepatitis, the part of the blood and lymphatic system: often – leukopenia; -eozinofiliya infrequently; very rarely – neutropenia, Laboratory tests: often – increased activity of serum transaminases (ALT, ACT);rarely – increased activity of gamma-glutamate transaminase; increase in total cholesterol concentration in serum triglycerides; part of the endocrine system: very rarely – hyperglycemia, diabetes Allergic reactions: seldom – hypersensitivity; angioedema, Stevens-Johnson syndrome, a skin rash, the part of the reproductive organs: rarely – priapism; Other: often – moderate fatigue, edema, weight gain, rarely – neuroleptic malignant syndrome, back pain, chest pain, low-grade fever, myalgia, dry skin, impaired vision. during treatment with quetiapine, a slight dose-dependent decrease in thyroid hormone levels, particularly total and free T 4 . The maximum decrease in total and free T 4 were registered during the first 2-4 weeks of therapy with quetiapine, with no further reduction in hormone levels during long-term treatment. There was no evidence of clinically significant changes in the concentration of thyroid stimulating hormone. In almost all cases, the level of total and free T 4 returned to baseline after discontinuation of therapy quetiapine, regardless of the duration of treatment, quetiapine, like other primobolan depot side effects antipsychotics may cause lengthening of the interval QT, but the clinical trials showed no correlation between the reception quetiapine and constant . QT prolongation In the abrupt cancellation of the drug withdrawal syndrome cases have been reported, accompanied by nausea, vomiting; rarely – insomnia.


    Overdosing Symptoms: drowsiness and excessive sedation, tachycardia and lowering blood pressure. Treatment: No specific antidote. In cases of severe intoxication – symptomatic treatment (maintenance of respiratory function, cardiovascular system, ensuring adequate oxygenation and ventilation). A careful medical monitoring and observation of the patient is needed to complete recovery.


    Interactions with other drugs lekrstvennymi
    Cytochrome P450 CYP3A4 is the primobolan depot side effects key enzyme involved in the metabolism of quetiapine. With simultaneous administration of these drugs possessing a strong inhibitory effect on cytochrome P450 CYP3A4 (azole antifungals group and macrolide antibiotics) in the plasma concentration of quetiapine may significantly increase. Thus, while appointing quetiapine and ketoconazole shown to increase the area under the curve (AUC) of quetiapine in 5.8 times. For this reason, the combination of these drugs are contraindicated. Also during treatment Lakvelem not recommended to consume grapefruit juice.
    When concomitant administration Lakvelya with drugs that induce liver enzyme system, such as carbamazepine or phenytoin, quetiapine plasma concentration decreases. You should carefully weigh the risks and benefits of co-administration Lakvelya and hepatic enzyme inducers (apart from those mentioned above, barbiturates, rifampicin). You may need to increase the dose Lakvelya, which is carried out progressively; should also consider replacing Lakvelya the drug without inducing microsomal liver enzymes (eg, valproic acid).
    The pharmacokinetics of lithium drugs does not change, while the appointment Lakvelya. Simultaneous treatment with antipsychotics risperidone or haloperidol had no significant effect on the pharmacokinetics of quetiapine. However, simultaneous thioridazine leads to increased clearance of quetiapine at about 70%. The pharmacokinetics of quetiapine are not significantly altered, while the application of cimetidine, an inhibitor of P450, and in conjunction with the appointment imipramine or fluoxetine. When concomitant administration of valproic acid and Lakvelya preparations of pharmacokinetic parameters did not change significantly. Drugs that suppress the central nervous system, as well as ethanol increases the risk of side effects.
    Caution must be exercised in the appointment of Lakvelya in combination with drugs that prolong the interval QT (neuroleptics, antiarrhythmics, halofantrine, mesoridazine, thioridazine, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, dolasetron mesylate, mefloquine, sertindole, cisapride), as well as drugs that cause electrolyte imbalance (thiazide diuretics).

    Specific guidance
    in the initial period of titration of orthostatic hypotension may occur. In this case, you should go back to the previously received a dose. Particular attention should be given to patients with cardiovascular diseases, cerebrovascular diseases and other conditions predisposing to hypotension.
    Antipsychotic drugs (neuroleptics), including quetiapine, contribute to the development of thromboembolic complications in patients with a predisposition to the formation of blood clots. Before initiation of therapy with quetiapine need to identify all possible risk factors for thromboembolism and venous vessels to take appropriate measures for the prevention of thromboembolic complications.
    There was no relationship between drug intake in the recommended mode and increased QT-interval. However, an increase in QT-interval in overdose noted. Caution should be exercised in the appointment of quetiapine in conjunction with drugs that prolong the interval of the QT the C , especially in the elderly, in patients primobolan depot side effects with congenital QT-syndrome, heart failure, cardiac hypertrophy, hypocalcaemia or hypomagnesemia, and in the presence of family history to increase QT- interval.
    It should be used with caution in combination with other drugs having inhibitory effect on the central nervous system, as well as alcohol. Care should be taken when treating patients with a history of seizures.In the treatment of quetiapine may develop neuroleptic malignant syndrome, the clinical manifestations of which include hyperthermia, altered mental status, muscular rigidity, instability of the autonomic nervous system, increased creatine phosphokinase levels. In such cases, a removal of the drug and appropriate therapy.
    It should also consider the possibility of tardive dyskinesia with prolonged use of quetiapine. In this case, you should reduce the dose or consider its abolition. With a sharp lifting treatment with high doses following acute reactions (withdrawal syndrome) can occur – nausea, vomiting, insomnia rarely. It is also possible exacerbation of psychotic symptoms of the disease and the emergence of involuntary movement disorders (akathisia, dystonia, dyskinesia). In this connection, the abolition of the drug is recommended to be made gradually.
    Lakvel not intended for the treatment of patients suffering from psychosis, accompanying senile dementia. There is evidence of increased risk of cerebrovascular events in patients primobolan depot side effects with senile dementia during treatment with atypical antipsychotics. Care should be taken when appointing Lakvelya patients with risk factors for stroke. Lakvel The drug contains lactose, so it is not indicated in patients with lactase deficiency or malabsorption of glucose and galactose.

    Effects on ability to drive and other mechanisms
    The drug can cause drowsiness, so the period of treatment is not recommended for patients: management of vehicles, work with mechanisms, which constitute a danger.


methenolone enanthate side effects


When administered methenolone enanthate side effects parenterally to degrade partially excreted unchanged mainly via the kidney. As with all interferons in individuals with prolonged use of the drug can cause the appearance of antibodies to interferon, which leads to a decrease in therapeutic effect.


  • in acute viral hepatitis B – moderate and severe forms of jaundice in the early period before the 5th day of jaundice (at a later date the appointment of the drug is less effective, the drug is not effective in developing hepatic coma and cholestatic disease course);
  • lingering in acute hepatitis B and C, chronic active hepatitis B, C and D with no signs of liver cirrhosis methenolone enanthate side effects and for symptoms of cirrhosis of the liver;
  • viral (influenza, adenovirus, enterovirus, herpes, mumps-tion), viral-bacterial and mycoplasma meningoencephalitis. Use of the drug is most effective during the first 4 days of the disease;
  • for viral conjunctivitis, keratoconjunctivites, keratitis, keratouveitis;
  • at stage IV kidney cancer, hairy cell methenolone enanthate side effects leukemia, malignant skin lymphoma (mycosis fungoides, primary reticulosis), Kaposi’s sarcoma, basal cell and squamous skin cancers, keratoacanthoma, chronic myeloid leukemia, gisteotsitoze-X subleukemic myelosis, essential thrombocytopenia;
  • in multiple sclerosis.
  • acute lymphoblastic leukemia methenolone enanthate side effects in remission after induction chemotherapy (4-5 month remission);
  • in juvenile respiratory papillomatosis of the larynx, starting from the day after the removal of warts.


In acute hepatitis B drug is administered at 1 million ME 2 times a day for 5-6 days and then the dose was reduced to 1 million IU per day and administered for a further 5 days. If necessary (after controlling biochemical studies of blood) treatment can be continued for 1 million ME 2 times a week for 2 weeks. Heading dose of 15-21 million ME.

Lingering in acute and chronic active hepatitis in the exclusion of delta infection and without cirrhosis methenolone enanthate side effects drug is administered at 1 million ME 2 times per week for 1-2 months. In the absence of the effect of treatment extended to 3-6 months or after 1-2 months of treatment to conduct similar 2-3 courses with an interval 1-6 months.

In acute and prolonged chronically active hepatitis C without cirrhosis drug is administered at 3 million ME 3 times a week for 6-8 months. In the absence of the effect of treatment extended to 12 months.Repeated treatment after 3-6 months.

In chronic active hepatitis D without cirrhosis drug is administered at 500 th – ME 1 million per day, 2 times a week for 1 month. Repeated treatment after 1-6 months.

In chronic active hepatitis B and D with signs of liver cirrhosis is administered at 250 -500 thousand daily ME 2 times a week for one month. When you see signs of decompensation conduct similar refresher courses at intervals of not less than two months.

When kidney cancer drug is methenolone enanthate side effects used for the ME 3 million daily for 10 days. Repeated courses of treatment (3-9 or more) is carried out at intervals of 3 weeks. Total amount of the preparation is from 120 million to 300 million ME ME or more.

When volosatokpetochnom leukemia drug is administered daily for 3-6 million ME for 2 months. After normalization of the hemogram daily dose is reduced to 1-2 million ME. Then at prescribed maintenance therapy 3 ME 2 million times a week for 6-7 weeks. The total amount of drug is ME 420-600 million or more.

In acute lymphoblastic leukemia in children after remission induction chemotherapy (4-5 months of remission) – 1 million by 1 ME once a week for 6 months and then every 1 to 2 weeks for 24 months. At the same time carry out maintenance chemotherapy.

In chronic myeloid leukemia drug methenolone enanthate side effects is administered 3 million daily ME or ME 6 million a day. Duration of treatment from 10 weeks to 6 months.

When gisteotsitoze-X drug is administered 3 million ME daily for 1 month, repeated courses with 1-2-month intervals for 1-3 years

When subleukemic myelosis and essential thrombocytopenia correction hyperthrombocytosis drug is administered 1 million ME daily or every other day for 1 to 20 days.

Malignant lymphoma and Kaposi’s sarcoma drug is administered at 3 million ME per day every day for 10 days in combination with cytostatics (prospidin, cyclophosphamide) and glucocorticosteroids. When tumor stage mycosis fungoides and retikulosarkomatoze advisable to alternate the intramuscular formulation of the 3 million ME and intralesional -by ME 2 million within 10 days.

When viral, bacterial, viral and mycoplasma meningoencephalitis drug is administered 1 million ME 2 times a day for 10 days, in combination with antiviral and antibacterial chemotherapy. The dosage and treatment regimen established individually, depending on the severity of the patient’s condition.

Patients eritrodermicheskoy stage mycosis fungoides with increasing temperature over 39 C, and in the case of aggravation of the process, the introduction of the drug should be discontinued. With insufficient therapeutic effect after 10-14 days appoint a second course of treatment. After reaching a clinical effect on maintenance therapy administered 3 million ME once a week for 6-7 weeks.

In juvenile laryngeal papillomatosis respiratory preparation administered ME 100-150 thousand per kg of body weight daily for 45-50 days, then at the same dosage three times a week for one month. The second and third courses are held at intervals of 2-6 months.

When multiple sclerosis drug appoint 1 million ME when pyramidal syndrome 3 times a day, with cerebellar syndrome – 1-2 times a day for 10 days followed by administration of 1 million ME 1 time per week for 5-6 months. The total amount of the drug is 50-60 million ME.

Individuals with high pyrogenic reaction (39 ° C and above) on administration of the drug recommended simultaneous application of indomethacin.

perifocal administration

When basal cell and squamous cell carcinoma, keratoacanthoma drug is injected under the lesion 1 million ME 1 times a day every day for 10 days. In the case of pronounced local inflammatory reactions by administering to the lesion is carried out in 1-2 days. On completion of the course, if necessary, carry out cryotherapy.

subconjunctival administration

If stromal keratitis and keratoiridoiiklitah appoint subconjunctival injection of the drug at a dose of 60 thousand ME in the volume of 0.5 ml daily or every other day depending on the severity of the process.Injection is performed under local anesthesia with 0.5% tetracaine solution. The course of treatment – from 15 to 25 injections.

topical application

For topical application to the drug vial contents with activity 1 million ME was added 4 ml of sodium chloride 0.9% for injection. In the case of storage solution you need the drug, observing the rules of aseptic and antiseptic, to transfer the contents of the vial into a sterile bottle with a cork and keep the solution in a refrigerator at 4-10 ° C for up to 12 hours.

When conjunctivitis and superficial keratitis in the conjunctiva of the affected eye is applied 2 drops of solution 6-8 times a day. With the disappearance of inflammatory phenomena number of instillations reduced to 3-4 per day. The course of treatment – 2 weeks.


Interferon alpha is able to reduce the methenolone enanthate side effects activity of cytochrome P-450 and, therefore, to intervene in the metabolism of cimetidine, phenytoin, chimes, theophylline, diazepam, propranolol, warfarin, certain cytostatics. It could enhance neurotoxic, myelotoxic, or cardiotoxic effects of drugs prescribed before or simultaneously with it. Avoid concomitant administration with drugs depressing the central nervous system, immunosuppressive drugs (including corticosteroids).

It is not recommended during treatment with drinking alcohol.


For parenteral administration of the drug may be chills, fever, fatigue, headache, malaise, flu-like symptoms. These side effects are partially cropped acetaminophen / paracetamol.

The local application of the drug on the mucous membrane of the eye may be conjunctival infection, redness of eyes, isolated follicles, swelling of the conjunctiva of the lower arch.

It is also possible abnormal laboratory methenolone enanthate side effects values, manifested leukopenia, lymphopenia, thrombocytopenia, increased ALT levels, alkaline phosphatase. For early detection of these abnormalities during therapy common clinical blood tests should be repeated every 2 weeks, and biochemical every 4 weeks. Generally, these changes are usually small, asymptomatic and reversible.

primobolan depot for sale

Intramuscular administration primobolan depot for sale the peak concentration achieved within 10 minutes in plasma. The distribution of ondansetron are equally intramuscular and intravenous administration. After oral administration, the maximum concentration of ondansetron in the blood plasma is reached after about 1.5 hours. Both after oral and parenteral administration, when the half-life is about 3 hours in the elderly may reach.Prevention and primobolan depot for sale elimination of nausea and vomiting induced by cytotoxic chemotherapy and / or radiotherapy and postoperative nausea and vomiting.

  • Hypersensitivity to ondansetron or any other component of the formulation.
  • Pregnancy and lactation.
  • Children under 2 years (safety and efficacy has not been studied)

Dosing and Administration

Cytostatic therapy
The choice of dosage primobolan depot for sale regimen is determined by the severity of the action carried out by emetogenic anticancer therapy.

For adults, the daily dose usually is 8-32 mg are recommended the following modes:

In moderate emetogeinoy chemotherapy or radiotherapy:

  • 8 mg slowly intravenously or intramuscularly, immediately before therapy;
  • 8 mg orally 1-2 hours prior to initiation of therapy, then an additional 8 mg orally after 12 hours after initiation of therapy.

When vysokoemetogennoy chemotherapy:

  • 8 mg slowly intravenously primobolan depot for sale immediately before the start of chemotherapy, followed by two more injections intravenously at 8 mg, each of which is carried out in 2-4 hours;
  • 24-hour continuous infusion of drug at a dose of 24 mg at 1 mg / hour;
  • 16-32 mg diluted in 50-100 ml of the appropriate infusion solution in the form of 15-minute infusion, immediately before chemotherapy.

BM Lazarana Efficiency may be increased by a single intravenous injection of a glucocorticoid (e.g., dexamethasone 20 mg) prior to chemotherapy; when administered to enhance the effect of a single dose may be increased to 24 mg, and assigned simultaneously with 12 mg of dexamethasone for 1-2 hours prior to chemotherapy. To prevent delayed (occurring within 24 hours after the start of chemotherapy or radiotherapy) emesis encouraged to continue to use the drug orally in the form of tablets 8 mg 2 times a day for 5 days.

Children over 2 years of drug is given at a dose of 5 mg / m2 body surface area intravenously, immediately before the start of chemotherapy, followed by ingestion of a primobolan depot for sale dose of 4 mg every 12 hours; after chemotherapy is recommended to continue the treatment at 4 mg twice a day orally for 5 days.

Prevention of postoperative nausea and vomiting
Adults administered a single dose of 4 mg intravenously or intramuscularly slowly at the beginning of the anesthesia or 16 mg orally administered for 1 hour before anesthesia.

For relief of nausea and vomiting arising recommended intramuscular or slow intravenous administration of 4 mg of the drug.

Intramuscularly in the same area of the body Lazaran VM can be administered in a dose not exceeding 4 mg!

Babies to prevent post-operative nausea and vomiting Lazaran VM applied exclusively parenterally in a single dose of 0.1 mg / kg (up to 4 mg) as a slow intravenous injection prior to or after anesthesia.

Which developed for the treatment of postoperative nausea and vomiting in children recommended slow intravenous administration of a single dose of 0.1 mg / kg of the drug (up to 4 mg). With regard to the prevention and treatment of postoperative nausea and vomiting in children under 2 years of experience is not sufficient.

Elderly patients
change the dosage is not required.

Patients with lesions of the kidney and the liver
If kidney damage alter the usual daily dose and frequency of dosing is required.

When liver disease is largely reduced clearance Lazarana VM, and increases its half-life of plasma, however, do not exceed the daily dose of 8 mg per day.

The following solutions can be used to reconstitute an injectable solution:
0.9% sodium chloride,
5% rastvordekstrozy,
Ringer’s solution,
0.3% chloride and 0.9% sodium chloride potassium,
0.3% potassium chloride primobolan depot for sale solution and 5% dextrose solution.

Side effects: Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis. From the digestive system: hiccups, dry mouth, diarrhea, constipation, sometimes asymptomatic transient increase in serum aminotransferase levels. On the part of the cardiovascular system: chest pain in some cases with the segment depression ST, arrhythmia, bradycardia, decreased blood pressure. from the nervous system: headache, dizziness, spontaneous movement disorders and seizures. Local reactions: pain, burning and redness at the injection site, Other: rush of blood to face, burning sensation, temporary disruption of visual acuity, hypokalemia.

Interactions with other drugs
Because ondansetron is metabolized by the enzyme system (cytochrome P450) of the liver, caution is required when used together:

  • P450 enzyme-inducers (of CYP2D6 and CYP3A) – barbiturates, carbamazepine, carisoprodol, glutetimid, griseofulvin, dinitrogen oxide, papaverine, phenylbutazone, phenytoin (probably other hydantoins), rifampicin, tolbutamide;
  • with inhibitors of P450 enzymes (CYP2D6 and CYP3A) – allopurinol, macrolide antibiotics, antidepressants – MAO inhibitors, chloramphenicol, cimetidine, oral contraceptives containing estrogens, diltiazem, disulfiram, valproic acid, sodium valproate, erythromycin, fluconazole, fluoroquinolones, isoniazid, ketoconazole, lovastatin, metronidazole, omeprazole, propranolol, quinidine, quinine, verapamil.

Lazaran VM at a concentration of 16-160 mg / ml pharmaceutically compatible and can be primobolan depot for sale administered through a Y-shaped injector / drip together with the following medicines:

  • tsisplastin (at a concentration of 0.48 mg / ml) for 1-8 hours;
  • 5-fluorouracil (at a concentration of 0.8 mg / ml at 20 ml / h – higher concentration may cause precipitation in the sludge Lazarana BM);
  • carboplatin (in a concentration of 0,18-9,9 mg / ml for 10-60 min);
  • etoposide (concentration 0,14-0,25 mg / ml for 30-60 min);
  • ceftazidime (at a dose of 0.25-2.0 g as an intravenous bolus injection over 5 min);
  • cyclophosphamide (at a dose of 0.1 -1.0 g, as an intravenous bolus injection over 5 min);
  • doxorubicin (at a dose of 10-100 mg, as an intravenous bolus injection over 5 min);
  • dexamethasone: possible intravenous dexamethasone 20 mg slowly, within 2-5 min. Drugs may be administered via a drip, with a solution of dexamethasone sodium phosphate concentrations can range from 2.5 .mu.g to 32 mg / ml, Lazarana BM – 8 mcg to 1 mg / ml.

In case of suspected overdose symptomatic therapy is shown. With an overdose of tablets of ondansetron is not recommended the use of ipecac, as it is unlikely that this primobolan depot for sale drug will be effective during the antiemetic effect of the drug. A specific antidote is not known.